‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Headline as filed by MarketWatch.
Compare coverage — 2 reports
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| MarketWatch | ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks |
The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so. |
0m | marketwatch.com | First Page headline | ||
| Gizmodo | Pharma Bro Martin Shkreli Could Be in Big Trouble Again |
The FTC says he's been trading pharma stocks. He's banned for life. |
3h | gizmodo.com | Latest |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Coverage analysis
PageNews compared 2 reports of this event on framing. Each score describes the language one report used, not whether it was right.
What this coverage raises
- Unresolved questions 1 of 2 reports
How many of the reports below framed this event in each of those terms, and how strongly. It records what publishers wrote about, not what will happen — PageNews makes no forecast and has no model of any of these.
Measured by PageNews from the headline and the publisher’s own summary, not from the full articles. Scores describe word choice and emphasis; the percentage beside each is confidence, which is separate from the score and lower when there was less text to read. How this is measured.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.